Efforts to enhance the efficacy of B7-H4 CAR-T therapy include strategies for reducing dosing duration, such as utilizing transient CAR expression through inducible suicide genes (85) or RNA electroporation (77, 86), as well as investigating combination therapies to augment anti-tumor efficacy. Here, CD80 is linked to neoplasm.